Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01019707 · ClinicalTrials.gov registry record · Phase 1
Safety Assessment of Atomoxetine With MA IV Administration
A Phase 1 study, sponsored by University of California, Los Angeles.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01019707 is a Phase 1 study that was terminated before completion, run by University of California, Los Angeles. The registered enrollment target is 6 participants.
The verdict
NCT01019707, a Phase 1 study, was terminated before completion, sponsored by University of California, Los Angeles.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a study of 4 nontreatment seeking individuals who were MA-dependent and the safety and tolerability of atomoxetine. This double-blind, placebo-controlled, within-subjects study is to determine the safety and tolerability of atomoxetine. MA abusing participants will undergo a 1-day outpatient screening and if it is safe for the participants to proceed with the study they will participate in two inpatient components of the study that will occur in the University of California Los Angeles (UCLA) General Clinical Research Center (GCRC). The first inpatient stay will be 15 days, and the second will be a 9 days stay that includes drug administration and assessments. There will be at least a two week interval between inpatient components. During the inpatient components participants will receive alternating study drugs; atomoxetine or placebo and four sessions of IV MA administration or saline.
Interventions
- DRUG Atomoxetine, then Placebo
- DRUG Placebo, then Atomoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01019707
The ClinicalTrials.gov registry entry for NCT01019707 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atomoxetine, then Placebo is the first listed.
NCT01019707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01019707 about?
NCT01019707 is a clinical study titled "Safety Assessment of Atomoxetine With MA IV Administration". This is a study of 4 nontreatment seeking individuals who were MA-dependent and the safety and tolerability of atomoxetine. This double-blind, placebo-controlled, within-subjects study is to determine the safety and tolerability of atomoxetine. MA abusing participants will undergo a 1-day outpatien...
What is the current status of trial NCT01019707?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2009-10. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01019707?
The interventions under investigation include: Atomoxetine, then Placebo (DRUG), Placebo, then Atomoxetine (DRUG).
Who is sponsoring clinical trial NCT01019707?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.